GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...

WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA ...

Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

In the PROTECT AF trial, patients randomized to left atrial appendage closure initially continued taking warfarin and aspirin to promote device endothelialization. At 45 days after the procedure, 86.8 ...

Percutaneously implanted devices designed to seal off the left atrial appendage (LAA) have been around for some time, but a recent study of surgical closure of the appendage might have a beneficial ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

San Francisco, CA and Caesarea, ISRAEL--InSeal Medical Ltd., developer of percutaneous vascular closure devices for large bore punctures, today announced the successful treatment of three patients ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

Percutaneous closure of patent foramen ovale (PFO) is a widely used procedure, but the long-term safety and efficacy of the technique have not been investigated. This prospective, observational, ...